A Long-term Observational Study on the Efficacy of SSRIs or Combined Treatment(SSRIs+ CBT) in Panic Disorder Patients
1 other identifier
observational
110
1 country
1
Brief Summary
It is known that the treatment of panic disorder with medication and psychotherapy are both effective. Representative as a treatment for panic disorder, Selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line treatment of panic disorder. In general, the initial reaction rate of panic disorder medication known to be frequently stopped early recurrence 70-80% It's too early, it is recommended that the duration of drug treatment for at least one year to be long-lasting. But whether it is appropriate for the duration of drug treatment to maintain a certain extent remains controversial, and maintain the medication for more than one year, even if the long-term effects known to be approximately 50% less than beyond being negative when remission based. Meanwhile, the typical method for the treatment of panic disorder psychology, cognitive behavioral therapy (Cognitive behavioral therapy) and looked comparable to the effect of the drug in the treatment of the known, especially in recent years when the combined treatment with medication can increase the long-term treatment of sexual reported that there's has been the subject of attention. But prospectively compare the long-term effects of these two treatments, research, especially the research about the long-term effects of the combined treatment with the drug treatment of panic disorder is very low, and almost nil is Researchers, drug treatment and the effect of the combined treatment in patients with panic disorder over two years prospective study to compare the plans were. And verification, the researchers performed only through this study by comparing the long-term effects of the combined treatment with medication combined treatment of medication to be more effective than if the reaction to the long-term treatment of panic disorder that can affect the clinical and biological factors navigate to evaluate them. In addition, long-term observational study, panic disorder patients' subjective quality of life actually improved to some extent on the map together proven to.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2012
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2012
CompletedFirst Submitted
Initial submission to the registry
August 24, 2012
CompletedFirst Posted
Study publicly available on registry
August 29, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2014
CompletedDecember 30, 2013
August 1, 2012
2.7 years
August 24, 2012
December 26, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
PDSS
one year
Eligibility Criteria
Panic disorder patients 20 years of age or older to visit the Samsung Seoul Hospital, and the Department of Mental Health, a foreign patients, patients who agreed to participate in this study will be of. Plan the patient-specific total of 100 patients on each drug treatment group and combined treatment group, 55 patients recruited by the first year of study commences 1 years F / U to enforce the number of subjects.
You may qualify if:
- Outpatients with panic disorder at the SMC
- PD patients who agree to participate in the clinical study
- PD patients who are over 20 years old
You may not qualify if:
- PD patients who have either severe medical illnesses or other psychiatric illnesses
- PD patients who are pregnant, or lactating
- PD patients who have suicidal idea
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Samsung Medical Center
Seoul, Seoul, 000000, South Korea
Biospecimen
whole blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
BumHee BH Yu, Ph.D
Samsung Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 24, 2012
First Posted
August 29, 2012
Study Start
February 1, 2012
Primary Completion
October 1, 2014
Study Completion
October 1, 2014
Last Updated
December 30, 2013
Record last verified: 2012-08